drug
diroximel fumarate DR
Marketedupdated 3mo agoby $BIIB BIOGEN INC.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying diroximel fumarate DR
- —A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- —A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- phase3A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
- phase3A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
- —A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
- —Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- —Study of Diroximel Fumarate in the Real-World Setting
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 20, 2033
~7.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Oct 29, 2033compositionUS 8669281
- Sep 20, 2033compositionUS 10080733
- Sep 20, 2033method-of-use (U-1384)US 9090558
News(1)
- ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a whileBiogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.fiercebiotech · 16d ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that